Abstract 1137P
Background
Modern therapies have significantly improved outcome for patients with melanoma brain metastases (MBM). Still, the prognosis is poor, and the optimal treatment strategy is not well defined. Here, we report on the survival outcomes of systemic and locoregional treatments in an unselected, nationwide population-based cohort of patients with MBM.
Methods
All patients diagnosed with MBM in Denmark between 2015-2022 were retrospectively included. Patients were identified using the Danish Metastatic Melanoma Database (DAMMED) and local records of surgery and radiotherapy. Data were obtained from patient records.
Results
A total of 838 patients were included. Median overall survival (mOS) of the entire cohort was 9.0 months, and 112 patients were alive >3 years after diagnosis of MBM. Treatment with immune checkpoint inhibitors (ICI), ipilimumab + nivolumab, resulted in an intracranial overall response rate (icORR) of 46%, and a 2-year OS of 49% whereas BRAF/MEK-inhibitors (BRAF/MEKi) resulted in an icORR of 56%, and 2-year OS of 20%. A subgroup of patients with symptomatic MBM, treated initially with BRAF/MEKi with planned shift to ICI, had an icORR of 70%, 2-year OS of 50% and reached the longest mOS of 26 months. Patients with meningeal carcinomatosis (n=67) had a mOS of 8.4 months. Systemic therapy significantly improved OS for these patients, but no survival benefit was observed for patients receiving ICI compared to BRAF/MEKi. In total, 230 patients underwent surgery for MBM; of these, 30 received postoperative stereotactic radiosurgery (SRS). Baseline characteristics were balanced between the two groups. No benefit in OS or intracranial progression free survival was observed for patients receiving postoperative SRS.
Conclusions
Modern systemic therapies have improved survival for real-world patients with MBM; BRAF/MEKi had the highest icORR while ICI generated more durable responses. Planned shift from BRAF/MEKi to ICI can lead to long-term survival in selected patients. Postoperative SRS for patients undergoing surgery for MBM is questioned as a standard procedure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.B. Friis: Non-Financial Interests, Personal, Other, Travel and conference expenses: MSD. M. Donia: Financial Interests, Personal, Invited Speaker, Teaching: Novartis, Roche; Financial Interests, Personal, Other, Advisor: Achilles Therapeutics; Non-Financial Interests, Other, Sub-investigator of clinical trial with connected translational research: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary data access: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary Data Access: Genentech; Other, Chairman of the Melanoma and Non-melanoma Skin Cancer Scientific Committee: Danish Medicines Council (Medicinrådet). C.A. Haslund: Financial Interests, Personal, Invited Speaker: MSD, GSK, BMS; Financial Interests, Institutional, Local PI: BMS, Tesaro, MSD, IO Biotech, Chimerix, Incyte; Financial Interests, Institutional, Coordinating PI: GSK, Celgene Aps. H. Schmidt: Other, Institutional, Other: Danish Medicines Council, Member of the Melanoma and Non-Melanoma Skin Cancer Scientific Committee. L. Bastholt: Non-Financial Interests, Advisory Role, Scientific committee under Danish Medicines Agency regarding new Treatments of Melanoma, Skin Cancer and Thyroid Cancer: Danish Medicines Agency. I. Svane: Financial Interests, Personal, Advisory Board: BMS, Pierre Fabre, Novartis; Financial Interests, Personal, Invited Speaker: MSD, Pierre Fabre, Novartis, Roche, BMS; Financial Interests, Personal, Writing Engagement: MSD; Financial Interests, Personal, Stocks/Shares, Cofounder and Founder Warrants: IO Biotech; Financial Interests, Institutional, Research Grant: Adaptimmune, Enara Bio, Lytix Biopharma, TILT Biotherapeutics; Financial Interests, Institutional, Funding: Evaxion; Non-Financial Interests, Principal Investigator: BMS, Novartis, Roche, TILT Biotherapeutics, Lytix Biopharma. E. Ellebæk: Financial Interests, Personal, Invited Speaker: Pierre Fabre, BMS, Novartis, MSD, Pfizer; Other, Travel and conference expenses: MSD, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13